Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315-324) epitope of human cytomegalovirus.
Cytotoxic T lymphocytes play a central role in the control of persistent human CMV (HCMV) infection and reactivation. In healthy virus carriers, the specific CD8(+) CTL response is almost entirely directed against the virion tegument protein pp65 and/or the 72-kDa major immediate early protein, IE1. Studies that included a large panel of HCMV(+) donors suggested that immunorelevance of pp65 and IE1 was directly related with individual HLA haplotype difference. Nevertheless, there are no data on the incidence of HCMV natural polymorphism on virus-specific CTL responses. To assess the impact of IE1 polymorphism on CTL response, we have sequenced in 103 clinical isolates the DNA region corresponding to IE1(315-324), an immunodominant epitope presented by HLA-A*0201 molecules. Seven peptidic variants were found with extensive difference in their frequencies. The response of four HLA-A*0201-restricted anti-IE1 T lymphocyte clones, which were previously generated from one donor against autologous B lymphoblastoid cells expressing a recombinant clinical variant of IE1, was then evaluated using target cells loaded with mutant synthetic peptides or expressing rIE1 variants. One of four clones, which have been sorted 19 times among 22 clones targeted against IE1(315-324), recognized six of the seven tested variant epitopes. All three other clones showed distinct reactivity patterns to target cells loaded with the different mutant peptides or expressing IE1 variants. Therefore, in the HLA-A2 context, clonal expansions of anti-IE1 memory CTLs may confer a protection against HCMV successive infections and reactivations by killing cells presenting most of the naturally occurring IE1(315-324) epitope variants.
Prod'homme
Virginie
V
Institut National de la Santé et de la Recherche Médicale Unité 463 and Laboratoire de Virologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France.
Retière
Christelle
C
Imbert-Marcille
Berthe-Marie
BM
Bonneville
Marc
M
Hallet
Marie-Martine
MM
D002460:Cell Line; D002461:Cell Line, Transformed; D002999:Clone Cells; D003587:Cytomegalovirus / Q000276:immunology* / Q000302:isolation & purification; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics* / Q000276:immunology; D016056:Immunodominant Epitopes / Q000235:genetics / Q000276:immunology*; D008213:Lymphocyte Activation / Q000235:genetics; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000235:genetics / Q000276:immunology*; D011110:Polymorphism, Genetic / Q000502:physiology*; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014764:Viral Proteins
D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; C088645:IE1 protein, cytomegalovirus; D017874:Immediate-Early Proteins; D016056:Immunodominant Epitopes; D010446:Peptide Fragments; D014764:Viral Proteins